Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
Higher or lower levels of certain immune cells in cancer patients may be associated with how well they respond to immunotherapy, according to preliminary results of a study conducted by researchers at the University of Pittsburgh Cancer Institute (UPCI).
The findings were presented at the American Association of Cancer Research (AACR) Annual Meeting in Washington, D.C., by Robert Ferris, M.D., Ph.D., UPMC Endowed Professor, chief of the Division of Head and Neck Surgery, and co-leader of the Cancer Immunology Program at UPCI.
The research was an extension of the recently completed CheckMate 141 Phase III clinical trial co-chaired by Dr. Ferris, which showed that the immunotherapy nivolumab significantly increases survival and causes fewer adverse side effects in patients with recurrent head and neck cancer.
However, the treatment was not equally effective in all the patients so Dr. Ferris and his team aimed to find out whether differences in the patients' immune system profiles could be associated with better response to immunotherapy.
The researchers found that higher levels of tumour-associated immune cells (TAICs) expressing the PD-L1 protein were associated with longer overall survival and greater likelihood of response to the drug nivolumab.
TAICs are immune cells that have infiltrated the tumour and are thought to play an important role in tumour growth.
In blood samples taken prior to the start of immunotherapy, the researchers also found that patients with higher levels of circulating CD8, or cytotoxic, T cells--also known as killer T cells--and lower levels of regulatory T cells were associated with better response to treatment.
"Our study shows that immune cells in the microenvironment around the tumour could play a critical role in how patients respond to immunotherapy. By determining the nature of these cells and how they are affected by treatments, we may be able to significantly improve the effectiveness of current therapies and help a greater number of patients," said Dr. Ferris.
Source: University of Pittsburgh
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.